Safety and efficacy of incobotulinumtoxin A as a potential treatment for poststroke spasticity

10Citations
Citations of this article
46Readers
Mendeley users who have this article in their library.

Abstract

Spasticity is a common disabling symptom for several neurological conditions. Botulinum toxin type A injection represents the gold standard treatment for focal spasticity after stroke showing efficacy, reversibility, and low prevalence of complications. In recent years, incobotulinumtoxinA, a new Botulinum toxin type A free of complexing proteins, has been used for treating several movement disorders with safety and efficacy. IncobotulinumtoxinA is currently approved for treating spasticity of the upper limb in stroke survivors, even if several studies described the use also in lower limb muscles. In the present review article, we examine the safety and effectiveness of incobotulinumtoxinA for the treatment of spasticity after stroke.

Cite

CITATION STYLE

APA

Santamato, A. (2016, January 27). Safety and efficacy of incobotulinumtoxin A as a potential treatment for poststroke spasticity. Neuropsychiatric Disease and Treatment. Dove Medical Press Ltd. https://doi.org/10.2147/NDT.S86978

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free